Deucravacitinib for moderate to severe plaque psoriasis

Abstract

Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.